U.S. FDA grants GrayMatters Health FDA  510(k) clearance

March 27, 2023 | By Sabrina Kestenbaum
U.S. FDA grants GrayMatters Health FDA  510(k) clearance

The company gained clearance to market its flagship product, Prism for PTSD, the first non-invasive, self-neuromodulation adjunct digital therapy for post-traumatic stress disorder (PTSD).

Related News

Podcast | Joy Grantee, Dr. Noam Sobel discusses groundbreaking research on olfaction with Andrew Huberman

Podcast | Joy Grantee, Dr. Noam Sobel discusses groundbreaking research on olfaction with Andrew Huberman

Read more

Haaretz Profiles Joy Grantee Dr. Richard J. Davidson

Haaretz Profiles Joy Grantee Dr. Richard J. Davidson

Read more

NYX wants to solve your sleep problems using AI

NYX wants to solve your sleep problems using AI

Read more

Add your name to our mailing list and bring much-needed joy to your inbox.

Join our mailing list now.
Subscribe